Logo image of BAI.AS

Odyssey Acquisition SA (BAI.AS) Stock Fundamental Analysis

AMS:BAI - Euronext Amsterdam - LU2355630455 - Common Stock - Currency: EUR

0.081  -0.01 (-14.74%)

Fundamental Rating

2

Taking everything into account, BAI scores 2 out of 10 in our fundamental rating. BAI was compared to 52 industry peers in the Pharmaceuticals industry. BAI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, BAI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BAI has reported negative net income.
BAI had a negative operating cash flow in the past year.
BAI.AS Yearly Net Income VS EBIT VS OCF VS FCFBAI.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -50M -100M -150M

1.2 Ratios

BAI has a worse Return On Assets (-54.61%) than 79.59% of its industry peers.
The Return On Equity of BAI (-73.07%) is worse than 75.51% of its industry peers.
Industry RankSector Rank
ROA -54.61%
ROE -73.07%
ROIC N/A
ROA(3y)-60.56%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BAI.AS Yearly ROA, ROE, ROICBAI.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BAI.AS Yearly Profit, Operating, Gross MarginsBAI.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

BAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BAI has more shares outstanding
The debt/assets ratio for BAI has been reduced compared to a year ago.
BAI.AS Yearly Shares OutstandingBAI.AS Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 50M 100M
BAI.AS Yearly Total Debt VS Total AssetsBAI.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

BAI has an Altman-Z score of -7.05. This is a bad value and indicates that BAI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.05, BAI is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
BAI has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, BAI belongs to the top of the industry, outperforming 81.63% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -7.05
ROIC/WACCN/A
WACC7.35%
BAI.AS Yearly LT Debt VS Equity VS FCFBAI.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 100M 200M

2.3 Liquidity

BAI has a Current Ratio of 3.30. This indicates that BAI is financially healthy and has no problem in meeting its short term obligations.
BAI's Current ratio of 3.30 is amongst the best of the industry. BAI outperforms 87.76% of its industry peers.
A Quick Ratio of 3.30 indicates that BAI has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.30, BAI belongs to the best of the industry, outperforming 89.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 3.3
BAI.AS Yearly Current Assets VS Current LiabilitesBAI.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

BAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.78%, which is quite impressive.
The Revenue for BAI has decreased by -55.80% in the past year. This is quite bad
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.91%
Revenue 1Y (TTM)-55.8%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.5%

3.2 Future

The Earnings Per Share is expected to grow by 23.43% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 20.26% on average over the next years. This is a very strong growth
EPS Next Y8.46%
EPS Next 2Y14.81%
EPS Next 3Y23.43%
EPS Next 5YN/A
Revenue Next Year-31.89%
Revenue Next 2Y-7.92%
Revenue Next 3Y19.4%
Revenue Next 5Y20.26%

3.3 Evolution

BAI.AS Yearly Revenue VS EstimatesBAI.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 2032 50M 100M 150M
BAI.AS Yearly EPS VS EstimatesBAI.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BAI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BAI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BAI.AS Price Earnings VS Forward Price EarningsBAI.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BAI.AS Per share dataBAI.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as BAI's earnings are expected to grow with 23.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.81%
EPS Next 3Y23.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BAI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Odyssey Acquisition SA

AMS:BAI (3/12/2025, 7:00:00 PM)

0.081

-0.01 (-14.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)N/A N/A
Inst Owners22.95%
Inst Owner ChangeN/A
Ins Owners23.71%
Ins Owner ChangeN/A
Market Cap11.58M
Analysts80
Price Target2.75 (3295.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)50%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.99
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.04
BVpS0.59
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.61%
ROE -73.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.56%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.04%
Cap/Sales 18.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 3.3
Altman-Z -7.05
F-Score1
WACC7.35%
ROIC/WACCN/A
Cap/Depr(3y)35.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)15.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.91%
EPS Next Y8.46%
EPS Next 2Y14.81%
EPS Next 3Y23.43%
EPS Next 5YN/A
Revenue 1Y (TTM)-55.8%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.5%
Revenue Next Year-31.89%
Revenue Next 2Y-7.92%
Revenue Next 3Y19.4%
Revenue Next 5Y20.26%
EBIT growth 1Y38.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.65%
EBIT Next 3Y20.43%
EBIT Next 5YN/A
FCF growth 1Y25.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.73%
OCF growth 3YN/A
OCF growth 5YN/A